Therapy Areas: Cardiovascular
Farxiga Demonstrated Unprecedented Reduction in the Risk of Kidney Failure and Cardiovascular or Renal Death in Patients with Chronic Kidney Disease in the Phase III DAPA-CKD Trial
1 September 2020 - - Detailed results from the ground-breaking Phase III DAPA-CKD trial showed that British-Swedish drugmaker AstraZeneca's (OTC: AZNCF) Farxiga (dapagliflozin) on top of standard of care reduced the composite measure of worsening of renal function or risk of cardiovascular or renal death by 39% compared to placebo (p
Login
Username:

Password: